231 related articles for article (PubMed ID: 25735668)
1. Development, optimization and evaluation of long chain nanolipid carrier for hepatic delivery of silymarin through lymphatic transport pathway.
Chaudhary S; Garg T; Murthy RS; Rath G; Goyal AK
Int J Pharm; 2015 May; 485(1-2):108-21. PubMed ID: 25735668
[TBL] [Abstract][Full Text] [Related]
2. Binary lipids-based nanostructured lipid carriers for improved oral bioavailability of silymarin.
Shangguan M; Lu Y; Qi J; Han J; Tian Z; Xie Y; Hu F; Yuan H; Wu W
J Biomater Appl; 2014 Feb; 28(6):887-96. PubMed ID: 24008629
[TBL] [Abstract][Full Text] [Related]
3. Enhanced bioavailability of silymarin by self-microemulsifying drug delivery system.
Wu W; Wang Y; Que L
Eur J Pharm Biopharm; 2006 Jul; 63(3):288-94. PubMed ID: 16527467
[TBL] [Abstract][Full Text] [Related]
4. Nanostructured lipid carriers for oral delivery of silymarin: Improving its absorption and in vivo efficacy in type 2 diabetes and metabolic syndrome model.
Piazzini V; Micheli L; Luceri C; D'Ambrosio M; Cinci L; Ghelardini C; Bilia AR; Di Cesare Mannelli L; Bergonzi MC
Int J Pharm; 2019 Dec; 572():118838. PubMed ID: 31715362
[TBL] [Abstract][Full Text] [Related]
5. Formulation and Optimization of Candesartan Cilexetil Nano Lipid Carrier: In Vitro and In Vivo Evaluation.
Paudel A; Ameeduzzafar ; Imam SS; Fazil M; Khan S; Hafeez A; Ahmad FJ; Ali A
Curr Drug Deliv; 2017; 14(7):1005-1015. PubMed ID: 28034361
[TBL] [Abstract][Full Text] [Related]
6. Nanostructured lipid carriers for improved oral delivery and prolonged antihyperlipidemic effect of simvastatin.
Fathi HA; Allam A; Elsabahy M; Fetih G; El-Badry M
Colloids Surf B Biointerfaces; 2018 Feb; 162():236-245. PubMed ID: 29197789
[TBL] [Abstract][Full Text] [Related]
7. Oil based nanocarrier for improved oral delivery of silymarin: In vitro and in vivo studies.
Parveen R; Baboota S; Ali J; Ahuja A; Vasudev SS; Ahmad S
Int J Pharm; 2011 Jul; 413(1-2):245-53. PubMed ID: 21549187
[TBL] [Abstract][Full Text] [Related]
8. Bioactive-Chylomicrons for Oral Lymphatic Targeting of Berberine Chloride: Novel Flow-Blockage Assay in Tissue-Based and Caco-2 Cell Line Models.
Elsheikh MA; Elnaggar YSR; Otify DY; Abdallah OY
Pharm Res; 2018 Jan; 35(1):18. PubMed ID: 29305670
[TBL] [Abstract][Full Text] [Related]
9. Application of Statistical Tooling Techniques for Designing of Carvedilol Nanolipid Transferosomes and its Dermatopharmacokinetic and Pharmacodynamic Studies.
Selvaraj BR; Sridhar SK; Kesavan BR; Palagati S
Pharm Nanotechnol; 2020; 8(6):452-470. PubMed ID: 32988361
[TBL] [Abstract][Full Text] [Related]
10. Chitosan-functionalized lipid-polymer hybrid nanoparticles for oral delivery of silymarin and enhanced lipid-lowering effect in NAFLD.
Liang J; Liu Y; Liu J; Li Z; Fan Q; Jiang Z; Yan F; Wang Z; Huang P; Feng N
J Nanobiotechnology; 2018 Sep; 16(1):64. PubMed ID: 30176941
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier.
Beloqui A; Solinís MÁ; Gascón AR; del Pozo-Rodríguez A; des Rieux A; Préat V
J Control Release; 2013 Mar; 166(2):115-23. PubMed ID: 23266764
[TBL] [Abstract][Full Text] [Related]
12. [Preparation of silymarin proliposomes and its pharmacokinetics in rats].
Xiao YY; Song YM; Chen ZP; Ping QN
Yao Xue Xue Bao; 2005 Aug; 40(8):758-63. PubMed ID: 16268514
[TBL] [Abstract][Full Text] [Related]
13. Quality by design approach to understand the process of optimization of iloperidone nanostructured lipid carriers for oral bioavailability enhancement.
Mandpe L; Pokharkar V
Pharm Dev Technol; 2015 May; 20(3):320-9. PubMed ID: 24328553
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel-loaded Nanolipidic Carriers with Improved Oral Bioavailability and Anticancer Activity against Human Liver Carcinoma.
Harshita ; Barkat MA; Rizwanullah M; Beg S; Pottoo FH; Siddiqui S; Ahmad FJ
AAPS PharmSciTech; 2019 Jan; 20(2):87. PubMed ID: 30675689
[TBL] [Abstract][Full Text] [Related]
15. Chlorogenic acid stabilized nanostructured lipid carriers (NLC) of atorvastatin: formulation, design and in vivo evaluation.
Khan S; Baboota S; Ali J; Narang RS; Narang JK
Drug Dev Ind Pharm; 2016; 42(2):209-20. PubMed ID: 26016780
[TBL] [Abstract][Full Text] [Related]
16. Improvement of oral bioavailability of lovastatin by using nanostructured lipid carriers.
Zhou J; Zhou D
Drug Des Devel Ther; 2015; 9():5269-75. PubMed ID: 26425076
[TBL] [Abstract][Full Text] [Related]
17. Development, optimization and evaluation of surfactant-based pulmonary nanolipid carrier system of paclitaxel for the management of drug resistance lung cancer using Box-Behnken design.
Kaur P; Garg T; Rath G; Murthy RS; Goyal AK
Drug Deliv; 2016 Jul; 23(6):1912-25. PubMed ID: 25544602
[TBL] [Abstract][Full Text] [Related]
18. Formulation of Nanomicelles to Improve the Solubility and the Oral Absorption of Silymarin.
Piazzini V; D'Ambrosio M; Luceri C; Cinci L; Landucci E; Bilia AR; Bergonzi MC
Molecules; 2019 Apr; 24(9):. PubMed ID: 31052197
[TBL] [Abstract][Full Text] [Related]
19. [Effect of particle size on oral absorption of silymarin-loaded solid lipid nanoparticles].
He J; Hou SX; Feng JF; Cai BQ
Zhongguo Zhong Yao Za Zhi; 2005 Nov; 30(21):1651-3. PubMed ID: 16400939
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the oral bioavailability of silymarin-loaded lipid nanoparticles with their artificial lipolysate counterparts: implications on the contribution of integral structure.
Shangguan M; Qi J; Lu Y; Wu W
Int J Pharm; 2015 Jul; 489(1-2):195-202. PubMed ID: 25956049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
